Roche Boston Consulting Group Matrix
Visual. Strategic. Downloadable.
Roche’s BCG Matrix snapshot shows how its key business units and product lines map across growth and market share—revealing potential Stars in oncology, Cash Cows in diagnostics, and areas at risk. This concise preview highlights strategic priorities and resource implications, but the full BCG Matrix delivers quadrant-level placements, actionable recommendations, and financial context. Purchase the complete report for a Word analysis and Excel summary that guide capital allocation, portfolio pruning, and growth bets with confidence.
Stars
Vabysmo (Faricimab)
Vabysmo (faricimab) is Roche’s high-growth ophthalmology star, with 2025 sales of CHF 4.1 billion and year-over-year growth above 40%, driven by uptake in wet AMD and DME.
Its flexible dosing (up to every 16 weeks) helped capture market share from Bayer/Regeneron’s Eylea, lowering treatment burden and boosting payer adoption in the US and EU.
Roche is investing in global rollout, real-world evidence programs and head-to-head studies; capex and H2 2025 field spend rose ~25% to secure long-term market leadership.
Phesgo (Breast Cancer)
Phesgo (breast cancer) is a Roche HER2 franchise star: a fixed-dose subcutaneous combo of pertuzumab and trastuzumab whose sales jumped >50% in 2025, reaching an estimated $1.2bn–$1.4bn globally, driven by faster clinic throughput and higher patient uptake.
Its convenience is rapidly taking share and blunting biosimilar threat, but Roche must fund geographic rollouts and convert IV patients; sustained investment will let Phesgo transition into a cash cow as market penetration exceeds 40% in key markets.
Ocrevus (Multiple Sclerosis)
Ocrevus remains Roche’s top-selling drug, posting CHF 7.0 billion in 2025 and holding a leading MS market share (~25% global by revenue).
The 2024 subcutaneous Zunovo launch broadened uptake—12% of 2025 Ocrevus prescriptions in Europe—and refreshed the brand, extending its lifecycle.
Despite product maturity, robust demand for novel MS therapies keeps Ocrevus in the BCG Stars quadrant: high market share and continued market growth ahead of patent expiries.
Hemlibra (Hemophilia A)
Hemlibra (emicizumab) transformed hemophilia A care, delivering double-digit growth to CHF 4.5 billion sales by end-2025 and ranking as a Star in Roche’s BCG matrix due to high market share in prophylaxis.
Roche holds dominant prophylaxis share, expanding into pediatric and inhibitor patients globally while investing in next-gen follow-ons to defend vs gene therapies and new competitors.
- CHF 4.5 billion sales (2025)
- Double-digit CAGR since 2022
- Leading global prophylaxis market share
- R&D on next-gen follow-ons vs gene therapy
Next-Generation Sequencing (NGS) Solutions
Roche Diagnostics is shifting to advanced sequencing with SBX, which Roche announced in November 2025 can decode a human genome in under four hours, targeting a personalized medicine market growing at ~14% CAGR to $45B by 2027.
The unit is first-to-market in clinical genomics, receiving >€1.2bn capex since 2024 to integrate diagnostics with Roche Pharma to drive companion diagnostics and targeted therapies.
- SBX: <4-hour genome (Nov 2025)
- Market: ~14% CAGR, ~$45B by 2027
- Investment: >€1.2bn capex since 2024
- Strategic goal: tie diagnostics to pharma for higher-margin care
Roche blockbuster surge: Vabysmo, Ocrevus, Hemlibra, Phesgo drive strong 2025 growth
Roche Stars: Vabysmo CHF4.1bn (2025, +40% YoY); Phesgo $1.3bn (2025, +50%); Ocrevus CHF7.0bn (2025, ~25% MS share); Hemlibra CHF4.5bn (2025, double-digit CAGR); Diagnostics SBX <4h genome (Nov 2025), >€1.2bn capex since 2024.
| Product | 2025 sales | Growth/notes |
|---|---|---|
| Vabysmo | CHF4.1bn | +40% YoY; q16w dosing |
| Phesgo | $1.3bn | +50%; subQ HER2 |
| Ocrevus | CHF7.0bn | ~25% MS rev share |
| Hemlibra | CHF4.5bn | double‑digit CAGR |
What is included in the product
Detailed Word Document
In-depth BCG review of Roche’s portfolio: Stars, Cash Cows, Question Marks, Dogs with strategic invest/hold/divest guidance.
Customizable Excel Spreadsheet
One-page Roche BCG Matrix mapping units into quadrants for fast strategic decisions and executive briefings.
Cash Cows
Diagnostics Division Core Lab Platforms
Roche’s Diagnostics division, led by centralized lab and pathology platforms, generated about CHF 13.8 billion in 2025, acting as a major cash cow for the group.
These mature, high-margin platforms hold dominant global shares in core lab and pathology, delivering predictable recurring revenue from consumables and service contracts.
Low growth but strong margins let Roche fund R&D (CHF 13.7 billion group R&D spend in 2024) and sustain dividends while driving efficiency gains to maximize free cash flow.
Alecensa (Lung Cancer)
Alecensa (alectinib) is Roche’s cash cow in ALK+ non‑small cell lung cancer, delivering stable sales around CHF 3.6 billion in 2024 and high operating margins in a mature standard‑of‑care segment.
Market adoption is entrenched—first‑line global share >60%—so promotional spend is low versus new launches, keeping net cash flow steady.
Roche redirects Alecensa profits to fund its oncology pipeline; Roche invested CHF 11.2 billion in R&D in 2024, much of which supports early‑stage cancer programs.
Xolair (Immunology)
Xolair (immunology) remains a Roche cash cow, holding top market share in chronic hives and asthma and driving CHF 2.8 billion in sales in 2025 after new food-allergy approvals. The underlying markets are mature, so marginal marketing and R&D costs are low while pricing stays stable. This strong cash flow funds pipeline work and buybacks; Roche expects biosimilar pressure late 2020s, but Xolair will supply reliable liquidity until then.
Diabetes Care (Accu-Chek)
The Accu-Chek franchise is a cornerstone of Roche’s diabetes care, delivering stable cash flow from ~30 million users worldwide and a >40% market share in strip-based SMBG (self-monitoring blood glucose) in 2024, in a mature market with low volume growth.
Pricing pressure and single-digit CAGR weigh on revenue, but optimized plants and >25% gross margins keep it a high-margin cash cow funding R&D into digital health and continuous glucose monitoring (CGM).
- ~30M users global
- 40% strip SMBG market share (2024)
- Single-digit CAGR; pricing pressure
- Gross margin >25%
- Funds CGM/digital health R&D
Perjeta (Oncology)
Perjeta (oncology) remains a high-volume HER2+ breast cancer drug, generating about CHF 2.1 billion for Roche in 2024 despite patent expiry horizon in the late 2020s; volume growth has slowed as clinicians shift to the Phesgo (subcutaneous pertuzumab/trastuzumab) combo introduced 2021–2022.
Established inclusion in adjuvant and metastatic protocols keeps Perjeta a steady cash source; Roche reported gross margins above 70% on the product in 2024 while prioritizing cost discipline and simplified supply to sustain returns before biosimilar entry intensifies.
- 2024 revenue ~CHF 2.1bn
- Growth slowing; Phesgo substitution since 2022
- Gross margin >70% (2024)
- Patent cliff late 2020s; biosimilar risk ahead
Roche’s high‑margin cash cows fund CHF13.7bn R&D & dividends amid biosimilar risk
Roche’s cash cows: Diagnostics platforms CHF 13.8bn (2025); Alecensa CHF 3.6bn (2024); Xolair CHF 2.8bn (2025); Accu‑Chek ~30M users, >40% SMBG share (2024); Perjeta CHF 2.1bn (2024). These mature, high‑margin businesses fund CHF 13.7bn group R&D (2024) and dividends while offsetting late‑2020s biosimilar risks.
| Asset | Revenue | Key metric |
|---|---|---|
| Diagnostics | CHF 13.8bn (2025) | Recurring consumables |
| Alecensa | CHF 3.6bn (2024) | 1st‑line share >60% |
| Xolair | CHF 2.8bn (2025) | Top immunology share |
| Accu‑Chek | — | ~30M users; >40% SMBG (2024) |
| Perjeta | CHF 2.1bn (2024) | Gross margin >70% |
Preview = Final Product
Roche BCG Matrix
The file you're previewing is the exact Roche BCG Matrix report you'll receive after purchase—fully formatted, analysis-ready, and free of watermarks or demo content. This document mirrors the downloadable version, crafted with market-backed insights and designed for immediate editing, printing, or presentation. Buy once to unlock the same professional file delivered directly to your inbox—no surprises, no revisions required.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Visual. Strategic. Downloadable.
Roche’s BCG Matrix snapshot shows how its key business units and product lines map across growth and market share—revealing potential Stars in oncology, Cash Cows in diagnostics, and areas at risk. This concise preview highlights strategic priorities and resource implications, but the full BCG Matrix delivers quadrant-level placements, actionable recommendations, and financial context. Purchase the complete report for a Word analysis and Excel summary that guide capital allocation, portfolio pruning, and growth bets with confidence.
Stars
Vabysmo (Faricimab)
Vabysmo (faricimab) is Roche’s high-growth ophthalmology star, with 2025 sales of CHF 4.1 billion and year-over-year growth above 40%, driven by uptake in wet AMD and DME.
Its flexible dosing (up to every 16 weeks) helped capture market share from Bayer/Regeneron’s Eylea, lowering treatment burden and boosting payer adoption in the US and EU.
Roche is investing in global rollout, real-world evidence programs and head-to-head studies; capex and H2 2025 field spend rose ~25% to secure long-term market leadership.
Phesgo (Breast Cancer)
Phesgo (breast cancer) is a Roche HER2 franchise star: a fixed-dose subcutaneous combo of pertuzumab and trastuzumab whose sales jumped >50% in 2025, reaching an estimated $1.2bn–$1.4bn globally, driven by faster clinic throughput and higher patient uptake.
Its convenience is rapidly taking share and blunting biosimilar threat, but Roche must fund geographic rollouts and convert IV patients; sustained investment will let Phesgo transition into a cash cow as market penetration exceeds 40% in key markets.
Ocrevus (Multiple Sclerosis)
Ocrevus remains Roche’s top-selling drug, posting CHF 7.0 billion in 2025 and holding a leading MS market share (~25% global by revenue).
The 2024 subcutaneous Zunovo launch broadened uptake—12% of 2025 Ocrevus prescriptions in Europe—and refreshed the brand, extending its lifecycle.
Despite product maturity, robust demand for novel MS therapies keeps Ocrevus in the BCG Stars quadrant: high market share and continued market growth ahead of patent expiries.
Hemlibra (Hemophilia A)
Hemlibra (emicizumab) transformed hemophilia A care, delivering double-digit growth to CHF 4.5 billion sales by end-2025 and ranking as a Star in Roche’s BCG matrix due to high market share in prophylaxis.
Roche holds dominant prophylaxis share, expanding into pediatric and inhibitor patients globally while investing in next-gen follow-ons to defend vs gene therapies and new competitors.
- CHF 4.5 billion sales (2025)
- Double-digit CAGR since 2022
- Leading global prophylaxis market share
- R&D on next-gen follow-ons vs gene therapy
Next-Generation Sequencing (NGS) Solutions
Roche Diagnostics is shifting to advanced sequencing with SBX, which Roche announced in November 2025 can decode a human genome in under four hours, targeting a personalized medicine market growing at ~14% CAGR to $45B by 2027.
The unit is first-to-market in clinical genomics, receiving >€1.2bn capex since 2024 to integrate diagnostics with Roche Pharma to drive companion diagnostics and targeted therapies.
- SBX: <4-hour genome (Nov 2025)
- Market: ~14% CAGR, ~$45B by 2027
- Investment: >€1.2bn capex since 2024
- Strategic goal: tie diagnostics to pharma for higher-margin care
Roche blockbuster surge: Vabysmo, Ocrevus, Hemlibra, Phesgo drive strong 2025 growth
Roche Stars: Vabysmo CHF4.1bn (2025, +40% YoY); Phesgo $1.3bn (2025, +50%); Ocrevus CHF7.0bn (2025, ~25% MS share); Hemlibra CHF4.5bn (2025, double-digit CAGR); Diagnostics SBX <4h genome (Nov 2025), >€1.2bn capex since 2024.
| Product | 2025 sales | Growth/notes |
|---|---|---|
| Vabysmo | CHF4.1bn | +40% YoY; q16w dosing |
| Phesgo | $1.3bn | +50%; subQ HER2 |
| Ocrevus | CHF7.0bn | ~25% MS rev share |
| Hemlibra | CHF4.5bn | double‑digit CAGR |
What is included in the product
Detailed Word Document
In-depth BCG review of Roche’s portfolio: Stars, Cash Cows, Question Marks, Dogs with strategic invest/hold/divest guidance.
Customizable Excel Spreadsheet
One-page Roche BCG Matrix mapping units into quadrants for fast strategic decisions and executive briefings.
Cash Cows
Diagnostics Division Core Lab Platforms
Roche’s Diagnostics division, led by centralized lab and pathology platforms, generated about CHF 13.8 billion in 2025, acting as a major cash cow for the group.
These mature, high-margin platforms hold dominant global shares in core lab and pathology, delivering predictable recurring revenue from consumables and service contracts.
Low growth but strong margins let Roche fund R&D (CHF 13.7 billion group R&D spend in 2024) and sustain dividends while driving efficiency gains to maximize free cash flow.
Alecensa (Lung Cancer)
Alecensa (alectinib) is Roche’s cash cow in ALK+ non‑small cell lung cancer, delivering stable sales around CHF 3.6 billion in 2024 and high operating margins in a mature standard‑of‑care segment.
Market adoption is entrenched—first‑line global share >60%—so promotional spend is low versus new launches, keeping net cash flow steady.
Roche redirects Alecensa profits to fund its oncology pipeline; Roche invested CHF 11.2 billion in R&D in 2024, much of which supports early‑stage cancer programs.
Xolair (Immunology)
Xolair (immunology) remains a Roche cash cow, holding top market share in chronic hives and asthma and driving CHF 2.8 billion in sales in 2025 after new food-allergy approvals. The underlying markets are mature, so marginal marketing and R&D costs are low while pricing stays stable. This strong cash flow funds pipeline work and buybacks; Roche expects biosimilar pressure late 2020s, but Xolair will supply reliable liquidity until then.
Diabetes Care (Accu-Chek)
The Accu-Chek franchise is a cornerstone of Roche’s diabetes care, delivering stable cash flow from ~30 million users worldwide and a >40% market share in strip-based SMBG (self-monitoring blood glucose) in 2024, in a mature market with low volume growth.
Pricing pressure and single-digit CAGR weigh on revenue, but optimized plants and >25% gross margins keep it a high-margin cash cow funding R&D into digital health and continuous glucose monitoring (CGM).
- ~30M users global
- 40% strip SMBG market share (2024)
- Single-digit CAGR; pricing pressure
- Gross margin >25%
- Funds CGM/digital health R&D
Perjeta (Oncology)
Perjeta (oncology) remains a high-volume HER2+ breast cancer drug, generating about CHF 2.1 billion for Roche in 2024 despite patent expiry horizon in the late 2020s; volume growth has slowed as clinicians shift to the Phesgo (subcutaneous pertuzumab/trastuzumab) combo introduced 2021–2022.
Established inclusion in adjuvant and metastatic protocols keeps Perjeta a steady cash source; Roche reported gross margins above 70% on the product in 2024 while prioritizing cost discipline and simplified supply to sustain returns before biosimilar entry intensifies.
- 2024 revenue ~CHF 2.1bn
- Growth slowing; Phesgo substitution since 2022
- Gross margin >70% (2024)
- Patent cliff late 2020s; biosimilar risk ahead
Roche’s high‑margin cash cows fund CHF13.7bn R&D & dividends amid biosimilar risk
Roche’s cash cows: Diagnostics platforms CHF 13.8bn (2025); Alecensa CHF 3.6bn (2024); Xolair CHF 2.8bn (2025); Accu‑Chek ~30M users, >40% SMBG share (2024); Perjeta CHF 2.1bn (2024). These mature, high‑margin businesses fund CHF 13.7bn group R&D (2024) and dividends while offsetting late‑2020s biosimilar risks.
| Asset | Revenue | Key metric |
|---|---|---|
| Diagnostics | CHF 13.8bn (2025) | Recurring consumables |
| Alecensa | CHF 3.6bn (2024) | 1st‑line share >60% |
| Xolair | CHF 2.8bn (2025) | Top immunology share |
| Accu‑Chek | — | ~30M users; >40% SMBG (2024) |
| Perjeta | CHF 2.1bn (2024) | Gross margin >70% |
Preview = Final Product
Roche BCG Matrix
The file you're previewing is the exact Roche BCG Matrix report you'll receive after purchase—fully formatted, analysis-ready, and free of watermarks or demo content. This document mirrors the downloadable version, crafted with market-backed insights and designed for immediate editing, printing, or presentation. Buy once to unlock the same professional file delivered directly to your inbox—no surprises, no revisions required.
